Kyle M. Kampman - Faculty Biosketch

Kyle M. Kampman, M.D.

Professor of Psychiatry at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Staff Physician, Veterans Affairs Medical Center, Philadelphia PA

Department: Psychiatry

Contact information

University of Pennsylvania
Center for Studies of Addiction
3535 market Street
Philadelphia, PA 19104

Office: 215 746 2764
Fax: 1215 746 2764

Email:
kampman@pennmedicine.upenn.edu

Education:
B.A. (Chemistry)
Northwestern University, 1981.
MD
Tulane University, 1985.

Post-Graduate Training
Intern in Medicine, Naval Hospital, Bethesda, 1985-1986.
Assistant Instructor in Psychiatry, Hospital of the University of Pennsylvania, Philadelphia, 1990-1993.
Fellowship, Addiction Psychiatry, University of Pennsylvania Treatment Research Center, Philadelphia, 1993-1994.

Certifications
American Board of Neurology and Psychiatry Certificate in Psychiatry , 1994.
American Board of Neurology and Psychiatry Certificate in Addiction Psychiatry , 1996.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, Piske M, Seaman SR, Bach P, Greenland S, Karim ME, Siebert U, Bruneau J, Gustafson P, Kampman K, Korthuis PT, Loughin T, McCandless LC, Platt RW, Schnepel KT, Socías ME.: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA Oct 2024.

Thakrar AP, Christine PJ, Siaw-Asamoah A, Spadaro A, Faude S, Snider CK, Delgado MK, Lowenstein M, Kampman K, Perrone J, Nelson LS, Kilaru AS.: Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open 7: e2435895, Sep 2024.

Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD.: Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. J Clin Psychiatry 84: 22br14567, Apr 2023.

Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, Tjoa CW, Marcus SC.: Not in my treatment center: Leadership's perception of barriers to MOUD adoption. J Subst Abuse Treat 2023.

French R, Worley J, Lowenstein M, Bogner HR, Calderbank T, DePhilippis D, Forrest A, Connolly Gibbons MB, Harris RA, Heywood S, Kampman K, Mandell DS, McKay JR, Newman ST, Oslin DW, Wadden S, Wolk CB.: Adapting psychotherapy in collaborative care for treating opioid use disorder and co-occurring psychiatric conditions in primary care. Fam Syst Health 2023.

Dugosh KL, Lent MR, Burkley SB, Millard CMK, McKay JR, Kampman KM.: Nonopioid Substance Use among Patients Who Recently Initiated Office-based Buprenorphine Treatment. J Addict Med 2023.

Krouse RA, Morales KH, Kampman KM, Chakravorty S.: The role of baseline insomnia in moderating the hypnotic properties of quetiapine. Addict Behav 2023.

114. Kuijper MF, Mahajan UV, Ku S, Barbosa DAN , Alessi SM, Stein SE , Kampman KM, Bentzley BS , Halpern CH: Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness Analysis Neuromodulation 25(2), Feb 2022.

Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.

Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.